Some items on our site have recently moved. Visit our News Hub for selected articles, special reports, podcasts and other resources.
Illumina’s $7.1 billion play for cancer startup Grail faces global headwinds
16 April 2021 00:00
On March 30, the US Federal Trade Commission challenged Illumina’s proposed acquisition of cancer diagnostic startup Grail, arguing that Illumina would have both the incentive and the ability to disadvantage Grail’s competitors by denying them access to its essential, next-generation sequencing technology. The deal has tapped into global regulatory concerns over vertical acquisitions, pharmaceutical deals and so-called killer acquisitions.
US Federal Trade Commission’s lawsuit to block Illumina’s acquisition of Grail contains ominous portents.
Illumina’s outrage at an attempt by the European Commission to capture a non-notifiable deal is a sign of the kind of backlash that a revision might bring.
James Panichi Senior Editor, Asia Pacific
James, an Australian journalist with over 25 years’ experience in print and electronic media, helps to oversee MLex’s coverage of regulatory risk in Asia, with special attention to Australia and New Zealand. In 2016, James was appointed as MLex’s managing editor for continental Europe, overseeing the Brussels bureau’s coverage of EU regulatory affairs and managing a team of 16 journalists in Brussels and Geneva. Previously James worked for the European Voice newspaper, before joining the... Read more
Flavia Fortes Global Head of Mergers
Flavia writes about merger control, antitrust enforcement and litigation in the U.S. and Brazil. Before joining MLex, Flavia worked as an Antitrust Consultant in the Federal Trade Commission's Office of International Affairs and as a Research Fellow for the American Antitrust Institute. She has written on the intersection of antitrust law and intellectual property law in technology-driven and innovative markets.Flavia holds a LL.M. in intellectual property from the George Washington University Law School and a... Read more